2-Year Change in Revised Hammersmith Scale Scores in a Large Cohort of Untreated Paediatric Type 2 and 3 SMA Participants

J Clin Med. 2023 Feb 28;12(5):1920. doi: 10.3390/jcm12051920.

Abstract

The Revised Hammersmith Scale (RHS) is a 36-item ordinal scale developed using clinical expertise and sound psychometrics to investigate motor function in participants with Spinal Muscular Atrophy (SMA). In this study, we investigate median change in the RHS score up to two years in paediatric SMA 2 and 3 participants and contextualise it to the Hammersmith Functional Motor Scale-Expanded (HFMSE). These change scores were considered by SMA type, motor function, and baseline RHS score. We consider a new transitional group, spanning crawlers, standers, and walkers-with-assistance, and analyse that alongside non-sitters, sitters, and walkers. The transitional group exhibit the most definitive change score trend, with an average 1-year decline of 3 points. In the weakest patients, we are most able to detect positive change in the RHS in the under-5 age group, whereas in the stronger patients, we are most able to detect decline in the RHS in the 8-13 age group. The RHS has a reduced floor effect compared to the HFMSE, although we show that the RHS should be used in conjunction with the RULM for participants scoring less than 20 points on the RHS. The timed items in the RHS have high between-participant variability, so participants with the same RHS total can be differentiated by their timed test items.

Keywords: motor function; natural history; spinal muscular atrophy.

Grants and funding

This study was supported, in the UK, by the SMA REACH UK project (www.smareachuk.org, accessed on 20 January 2023). FM is the chief investigator of the SMA Reach project. Commercial funding for the SMA Reach project is provided by Biogen Inc. (REC reference: 13/LO/1748, IRAS project ID: 122521), via UCL and GOSH. Historically, funding of the SMA Reach Project has also been provided by Muscular Dystrophy UK (07DN02; 37787 http://www.musculardystrophyuk.org/grants/clinical-trial-coordinators/, accessed on 20 January 2023), the MRC Translational Research Centre at UCL and Newcastle (MR/K501074/1), and the National Institute for Health Research Biomedical Research Centre (515048) at Great Ormond Street Hospital for Children NHS Foundation Trust and University College London (http://www.gosh.nhs.uk/research-and-innovation/nihr-great-ormond-street-brc/about-brc, accessed on 20 January 2023). The Pediatric Neuromuscular Clinical Research (PNCR) Network for SMA (Boston Children’s Hospital, Children’s Hospital of Philadelphia, Vagelos College of Physicians and Surgeons, Columbia University, New York; Nemours Children’s Hospital, Orlando; and Stanford University, Palo Alto) gratefully acknowledges the support of the SMA Foundation and Cure SMA. The support of Famiglie SMA, Telethon (GSP 13002), and ASAMSI to the Nemo Center in Rome and to the Italian network is gratefully acknowledged.